Activation of MAP kinase leads to the activation of p53-dependent pathways, and vice-versa. Although the amount of p53 protein increases in response to MAP kinase-dependent signaling, the basis of this increase is not yet fully understood. We have isolated the mutant cell line AP14, defective in p53 expression, from human HT1080 ®brosarcoma cells, which have an activated ras allele. The expression of p53 mRNA and protein is *10-fold lower in AP14 cells than in the parental cells. The high constitutive phosphorylation and activities of the MAP kinases ERK1 and ERK2 in HT1080 cells are greatly reduced in AP14 cells, although the levels of these proteins are unchanged, suggesting that the defect in the mutant cells aects the steady-state phosphorylation of ERK1 and ERK2. Overexpression of ERK2 in AP14 cells restored both MAP kinase activity and p53 expression, and incubation of the mutant cells with the phosphatase inhibitor orthovanadate resulted in strong coordinate elevation of MAP kinase activity and p53 expression. The levels of expression of the p53-regulated gene p21 parallel those of p53 throughout, showing that basal p21 expression depends on p53. The levels of p53 mRNA increased by 5 ± 8-fold when activated ras was introduced into wild-type cells, and the levels of the p53 and p21 proteins decreased substantially in wild-type cells treated with the MEK inhibitor U0216. We conclude that MAP kinase-dependent pathways help to regulate p53 levels by regulating the expression of p53 mRNA. Oncogene (2001) 20, 2527 ± 2536.
Introduction
The tumor suppressor p53 plays a key role in regulating cell cycle progression in response to a variety of genotoxic stresses and to the activation of oncogenes. The multiple pathways that either induce p53 or respond to it comprise a complex network (Agarwal et al., 1998; Vogelstein et al., 2000) . The regulation of p53-dependent functions involves both the accumulation and activation of the p53 protein in response to a variety of covalent modi®cations. Dierent modi®ed forms of p53 form complexes with a diverse set of regulatory proteins and thus dierentially change patterns of gene expression. The dierentially expressed proteins then drive distinct biological responses: cell cycle arrest, apoptosis, control of genome integrity, regulation of DNA repair, etc. (Ko and Prives, 1996; Levine, 1997; Agarwal et al., 1998; Giaccia and Kastan, 1998) .
In their discovery of cooperating oncogenes, Land et al. (1983) showed that the growth arrest exhibited by normal cells in response to activated ras alleles could be alleviated by additionally interfering with p53-or Rb-dependent pathways. We now know that activated RAS stimulates the synthesis of high levels of the cell cycle inhibitor p16 and also of p53, and thus of the p53-dependent inhibitor p21 (reviewed by Weinberg, 1997; Sherr, 2000) . A further interaction between the RAS and p53 pathways involves the protein ARF, which is induced by growth factor-dependent stimuli, including those mediated by RAS. ARF sequesters the p53 inhibitor MDM2, thus increasing the steady-state level of p53 (reviewed by Sherr, 2000) . Because activation of the ARF-MDM2-p53 pathway is known to increase the level of p53 by stabilizing the protein, and because a wealth of literature shows that a variety of stresses increase the levels of p53 protein by a similar mechanism, the increase in levels of p53 in response to activated MAP kinase signaling (Serrano et al., 1997; Fukasawa and Vande Wonde, 1997; Lin et al., 1998) has been asumed to be due to protein stabilization and thus has not been studied further.
We have developed methods for isolating and complementing mammalian cell lines carrying signaling mutations caused by chemical mutagenesis and have applied these methods to interferon-dependent and interleukin-1-dependent pathways Stark and Gudkov, 1999; Li et al., 1999) . To bring this approach to bear on p53-dependent signaling, we employed the human ®brosarcoma cell line HT1080, which harbors an N-ras mutation (Plattner et al., 1996) and thus expresses high levels of p53. Although the p53 of HT1080 cells is wild-type and drives p21 expression, these cancer cells do not arrest, even in response to the additional expression of exogenous wild-type p53, due to additional unknown mutations. Selectable marker genes under the control of a p53-dependent promoter are overexpressed constitutively in HT1080 cells and, following chemical mutagenesis, mutant lines can be obtained in which this p53-dependent expression is greatly reduced. In one such line, AP14, we noted a close correspondence between ERK activation and p53 mRNA levels.
Results

A mutant cell line defective in p53 expression
Clone AP14 was isolated from mutagenized H10 cells, HT1080-derived cells in which the expression of a cellsurface marker is regulated by a p53-dependent promoter. The basal expression of p53 protein is much reduced in AP14 cells, but the protein is still induced in response to treatment with N-phosphonacetyl-L-aspartate (PALA) or adriamycin ( Figure 1a ). To examine the transcriptional activation of p53, H10 and AP14 cells were transfected transiently with p53conA.luc and treated with PALA for 48 h or with adriamycin for 24 h (Figure 1b) . The basal level of luciferase was reduced by *10-fold in AP14 cells compared to the level in H10 cells. However, after treatment with either PALA or adriamycin, the luciferase activity increased in both the mutant and wild-type cells, suggesting that the relative degree of induction of p53 and its activation are not dierent in the two cell lines and that the major dierence is in the basal levels of p53. To determine whether the decrease in basal expression of p53 is due to altered protein stability, we treated AP14 and parental H10 cells with the protein synthesis inhibitor cycloheximide (25 mg/ml) for 15, 30, 60, 90, or 120 min and analysed the levels of p53 in Western transfers. Based on densitometric quanti®cation of the intensity of bands in an autoradiograph (data not shown), we found that the half-life of p53 is *15 min in AP14 cells and *30 min in H10 cells. This dierence in stability can account for only a small part of the dierence in p53 protein levels. Northern analysis revealed that the basal level of p53 mRNA is about 10-fold lower in AP14 cells than in parental H10 cells (Figure 1c ). There was a modest (2 ± 3-fold) increase in the levels of mRNA after treatment with adriamycin in both cell lines (data not shown). To investigate whether the low level of p53 mRNA in AP14 cells is due to decreased mRNA stability, the cells were treated with actinomycin D (5 mg/ml) for 0.5, 1, 2 or 4 h and p53 mRNA was analysed in Northern transfers. The rates of degradation of the mRNA were the same in AP14 and H10 cells (data not shown). RNase protection was used to examine the expression of two p53 target genes, p21 and gadd45. The basal level of p21 mRNA is virtually undetectable in AP14 cells, compared to H10 cells (Figure 1d ), but p21 is induced in both cell types after treatment with PALA ( Figure 1d fold lower in AP14 cells. The basal expression of gadd45 was decreased only slightly in AP14 cells and the induced levels were similar to those in H10 cells (Figure 1d) . Thus, the mutation in AP14 cells does not aect the ability of p53 protein to be induced but reduces the basal levels of p53 protein and mRNA substantially. The induction of gadd45 mRNA is less sensitive to the reduced amount of p53 in AP14 cells than is the induction of p21 mRNA. To test the dominance of the mutation, AP14 cells were fused with p53-de®cient MDAH041 cells. p53 mRNA expression was restored in the heterokaryons (Figure 1e) , indicating that the defect in AP14 is recessive.
MAP kinase activity regulates basal p53 expression H10 and AP14 cells are derived from human HT1080 ®brosarcoma cells, which harbor an activated N-ras allele (Plattner et al., 1996) , express constitutively elevated basal levels of MAP kinase activity (data not shown) and elevated basal levels of p53 and p21 proteins compared to normal human W138 cells (Figure 2 ). To investigate the basis of the defect in AP14 cells, we examined the status of several components of the RAS-MAP kinase signaling pathway. Western analysis of lysates of parental H10 and mutant AP14 cells, using an antibody speci®c for active ERK1 and ERK2 (Nishida and Botoh, 1993) , revealed that the constitutive phosphorylation of both kinases on the regulatory TEY sequence is greatly reduced in AP14 cells (Figure 3a) . The de®ciency in phosphorylated, active MAP kinase was con®rmed by speci®cally immunoprecipitating MAP kinase from AP14 and H10 cells and measuring its activity in a direct kinase assay, using myelin basic protein as a substrate. Under conditions of either serum starvation or growth in normal medium containing 10% serum, AP14 cells have much less basal MAP kinase activity than parental H10 cells (Figure 3b ). Western analysis indicated that AP14 and H10 cells have similar levels of ERK1 (data not shown) and ERK2 proteins ( Figure  3a) , demonstrating that the loss of MAP kinase activity is not due to reduced expression of either protein.
AP14 cells were transfected stably with cDNA encoding hemagglutinin (HA)-tagged wild-type ERK2 protein and the resulting cell line, AP14/ERK, expressing ectopic HA-tagged ERK2 (Figure 3a) , was analysed. Overexpression of ERK2 restored the expression of p53 and p21 proteins and mRNAs in AP14 cells, to levels comparable to those of parental H10 cells (Figure 3a,c) . Overexpression of ERK2 in AP14 cells also restored constitutive MAP kinase activity, as determined by Western analysis for phosphorylated ERK1 and ERK2 (Figure 3a) and by a direct kinase assay (Figure 3b ), to levels comparable to those of parental H10 cells. These data suggest that the level of MAP kinase activity may determine the levels of p53 and p21 mRNAs and proteins and that the defect in AP14 cells may be in the activation of MAP kinase.
Several mediators of RAS-RAF-MEK-MAP kinase signaling are unchanged in AP14 cells
Since HT1080 cells carry an activating Q61K mutation in N-ras and since AP14 cells exhibit low levels of MAP kinase activity, we investigated the status of signaling components between MAP kinase and RAS in the mutant cell line. We sequenced the N-ras gene of AP14 cells and found that the mutation was still intact (data not shown). Since Hamilton and Wolfman (1998) have shown that RAF-1 is constitutively associated with N-RAS in cells transformed with N-ras Q61K, we investigated this association in AP14 cells. Using a speci®c antiserum (Hamilton and Wolfman, 1998) , N-RAS was immunoprecipitated from H10 and AP14 cell extracts and analysed for co-precipitated RAF-1 (Figure 4a) . A similar amount of RAF-1 is associated with N-RAS in both cell lines, eliminating the Figure 2 Western analyses of p53 and p21 protein levels. Cells were treated with camptothecin (1 mg/ml) for 24 h. Equal amounts of total protein were loaded in each track of the gel MAP kinase activity. MAP kinase was immunoprecipitated with an antibody that recognizes both ERK1 and ERK2 and its activity was measured in a direct kinase assay with myelin basic protein as substrate (Moodie et al., 1993) . (c) Northern analysis of basal expression of p53 and p21 mRNAs possibility that the defect in AP14 cells is due to either a reduction in the amount of RAF-1 or to failure of RAF-1 to associate with N-RAS. RAF-1 activates MEK1 (Kyriakis et al., 1992) , the dual-speci®city kinase responsible for phosphorylating and activating ERK1 and ERK2. Therefore, we determined whether a change in MEK1 activity was responsible for the reduction of MAP kinase activity in AP14 cells. MEK1 was immunoprecipitated from total cell lysates prepared from H10, AP14 and AP14/ERK cells and incubated with kinase-dead GST-tagged ERK1 in the presence of 32 P-labeled ATP. Immunoprecipitated MEK1 from all three cell lysates had similar activity towards ERK1 (Figure 4b ), indicating that the defect in AP14 cells is not at the level of MEK1 activity.
Inhibition of basal tyrosine phosphatase activity induces p53 in AP14 cells
The experiments above suggested that the signaling components between RAS and MAP kinase are unchanged in AP14 cells. MAP kinase activity can be modulated by the speci®c phosphatase MKP1 (Chu et al., 1996) . In order to investigate whether a phosphatase is involved in the reduced activity of endogenous MAP kinase and whether MAP kinase is capable of being activated in AP14 cells, we performed several experiments. After preincubation with the phosphatase inhibitor sodium orthovanadate (50 mM for 24 or 48 h), lysates of AP14 cells were analysed for MAP kinase activity. Orthovanadate induced the phosphorylation of both ERK1 and ERK2, determined with an antibody that recognizes the phosphorylated, activated forms of these proteins (Figure 5a ). The phosphorylation of ERK1 and ERK2 was correlated with an elevation in basal MAP kinase activity, measured by immunoprecipitating these proteins, followed by a direct kinase assay (Figure 5b ). The level of orthovanadate-induced phosphorylation of ERK1 and ERK2 in AP14 cells was comparable to the basal levels in untreated H10 cells (Figure 5a ). Western analyses revealed that orthovanadate also increased the expression of p53 and p21 in AP14 cells (Figure 5c ). These observations con®rm that the defect in AP14 cells is not in MAP kinase itself, since both ERK1 and ERK2 can be speci®cally phosphorylated on their regulatory TEY sequences and since MAP kinase activity can be stimulated. The defect may lie in a component that inhibits MAP kinase activity independently of the MEK-regulated circuitry.
Since a phosphatase inhibitor restored the lost activity of MAP kinase and correspondingly, p53 and p21 expression of AP14 cells, we measured the levels of MKP1. Lysates of H10 and AP14 cells were analysed in Western transfers by using the polyclonal antibody C19. Although the levels of MKP1 are comparable in both cell lines (Figure 4c ), its activity might be modi®ed in AP14 cells. However, due to lack of appropriate reagents we were not able to assay the activity of this phosphatase. Since MAP kinase activity can be in¯uenced by a complex of scaolding proteins (Schaeer et al., 1998) , lysates of H10 and AP14 cells were analysed in Western transfers by using an antibody directed against the scaolding protein MP1 (Figure 4c ). There was no dierence between AP14 and H10 cells.
Oncogenic RAS stimulates increased p53 mRNA levels
To investigate further whether the RAS-mediated increase in p53 protein is a direct result of an increase in the expression of p53 mRNA, oncogenic H-ras V12 was introduced into populations of REF52 and NIH3T3 cells using a high-titer ecotropic retrovirus. In parallel infections, the percentage of infected cells varied between 50 ± 70%, estimated with a virus expressing green¯uorescent protein (data not shown). Infected populations were analysed after 0, 2, 4 and 6 days for the expression of ras and p53 mRNAs ( Figure  6 ). Expression of mutant RAS led to a 5 ± 8-fold increase in p53 mRNA in REF52 and NIH3T3 cells. These observations further establish that a substantial part of the RAS-mediated increase in p53 protein levels comes from an increase in the level of p53 mRNA. To investigate whether the p53 mRNA induced by oncogenic ras can be translated in p53 protein, we analysed, in parallel experiments, ras-infected cells for the expression of p53 and p21 proteins (Figure 6b ).
The increase in p53 mRNA corresponded to an increase in p53 protein. To further validate the role of MAPK in regulating p53 mRNA expression, we used the MEK inhibitor U0216, known to modulate MAPK activity (Favata et al., 1998) . H10 cells treated with 10 mM U0216 were analysed for p53 and p21 expression (Figure 6c ). The MAPK inhibitor caused both p53 and p21 levels to decrease in H10 cells, further implicating the MAPK pathway in positive regulation of p53 expression.
The constitutive expression of p21 is dependent on basal p53
The basal expression of p21 is much reduced in AP14 cells compared to H10 cells (Figure 1d ). Since p21 levels are known to increase upon activation of p53, we investigated whether the constitutive expression of p21 is a direct result of increased p53 levels. A system for regulated expression of wild-type p53 using a tetracyline-responsive promoter in p53-null MDAH041 cells was employed. In MDAH041 cells, p53 and p21 were not detected, but introduction of p53 restored the expression of p21 in two independent cell lines ( Figure  7 and data not shown). Furthermore, withdrawal of tetracycline led to an increase in both p53 and p21 levels ( Figure 7) . Additional evidence for the constitutive regulation of p21 by p53 comes from the observation that reintroduction of MAP kinase into AP14 cells restored the levels of p53 and p21 correspondingly (Figure 3c ). 
Discussion
Relationships between p53 and MAP kinase It has been known for some time that activation of MAP kinase-dependent pathways leads to increased levels of p53 and subsequently to stimulation of p53-dependent physiological responses such as apoptosis and cell-cycle arrest. As summarized in Figure 8 , several proteins regulate p53 expression, at the levels of both p53 protein and mRNA. A part of the increase in p53 in response to MAP kinase is due to up-regulation of ARF expression, leading to stabilization of p53 by sequestering its negative regulator MDM2. The work in this manuscript reveals that MAP kinase-dependent pathways also regulate p53 at another level entirely, stimulating an important increase in p53 mRNA, probably by stimulating transcription of the p53 gene. Recently, HoxA5 and Maf have been shown to activate the p53 promoter directly (Raman et al., 2000) . It is not yet known if these proteins are important in upregulating the expression of p53 mRNA in response to RAS. In addition, the p53 promoter contains binding sites for ETS1 and ETS2, transcription factors that mediate the upregulation of a number of genes in response to RAS (Venanzoni et al., 1996) . It is not known if the ETS-binding elements in the p53 promoter are important in increasing p53 expression in cells containing activated RAS.
Our observations raise the important issue of how p53 levels are regulated in growing cells, continuously exposed to growth factors that drive MAP kinase-dependent pathways. One would expect that exposure of quiescent cells to growth factors would increase p53 expression in the absence of any stress or DNA damage, by the mechanisms noted above. The physiological relevance of this mode of regulation is not obvious, since elevated levels of p53 are usually associated with cell cycle arrest. It is also notable that, as observed by others (Tang et al., 1998) and con®rmed here, the basal expression of the important cell cycle inhibitor p21 is highly dependent upon basal levels of p53, and again this eect is not due to a response of the cells to any stress. Although p21 expression is regulated in a complex manner by several dierent factors (Gartel and Tyner, 1999) , it is clear that p53 has a dominant in¯uence.
Finally, it is important to appreciate the reciprocal up-regulation of MAP kinase signaling in response to p53, as revealed by the recent work of Lee et al. (2000) , who suggest that p53 may stimulate the secretion of a growth factor that stimulates the RAS-MAP kinase pathway. Thus, p53 and MAP kinase each seem to reinforce the responses to the other protein, constituting a positive regulatory loop. The range of cells in which this reinforcement is eective and the physiological consequences remain to be determined.
Properties of mutant AP14
It is clear that the regulation of basal expression of p53 is distinct from stimulus-based induction. The half life of the p53 protein in AP14 cells is lower than in parental H10 cells. The small decrease does not account for the major dierence in protein levels, which is primarily due to low p53 mRNA levels in AP14 cells. We could not determine the rate of p53 transcription in AP14 cells because of the diculty of performing run-on assays with very little mRNA, but it is likely that p53 mRNA levels are regulated transcriptionally since we did not ®nd any dierence in the stability of p53 mRNA in AP14 and H10 cells. Detailed analysis of the p53 promoter elements required for MAP kinase-driven transcription will help to clarify this issue. We also observed a modest increase (2 ± 3-fold) in p53 mRNA after treatment of Figure 7 Western analysis of p21 expression in ®broblasts with tetracycline-regulated p53. The cells were grown in the tetracycline concentrations shown for 24 h and total cell lysates (67 mg total protein) were analysed using the monoclonal antibodies C-17-HRP for p21 or DO-1 for p53. MDAH041 cells, devoid of p53, are shown as a control Figure 8 Regulatory interrelationships between MAP kinase and p53 either H10 or AP14 cells with adriamycin after 24 h. This increase could have resulted from a primary increase in p53 protein, which might then have bound to elements in its own promoter (Dee et al., 1993) .
In response to DNA damage or other stresses, p53 modulates the expression of many dierent target genes. Analysis of mRNA induction for two known targets, p21 and gadd45, revealed dierential regulation, again supporting the concept that p53 modulates the expression of downstream eector genes dierently. The physiological importance of such dierential regulation remains to be determined. Our observation that the constitutive expression of p21 was greatly diminished upon loss of p53 in AP14 cells and restored upon restoration of p53 in AP14/ERK cells indicates that basal p21 expression in normal growing cells (where MAP kinase is activated by growth factors) depends on p53, even in the absence of any stress. This point was unequivocally con®rmed by analysing p21 expression in cells with tetracycline-regulated wild-type p53.
Further characterization of AP14 allows the RAS-RAF-MAP kinase pathway to be connected to the basal regulation of p53. The RAS-RAF-MAP kinase cascade has been implicated previously in the regulation of p53-mediated biological functions (Serrano et al., 1997; Fukasawa et al., 1997; Zhu et al., 1998) . Activated RAS proteins can stimulate the MAP kinase cascade persistently through their physical association with the critical regulatory kinase of the cascade, RAF-1 (Schaeer et al., 1998) . The unknown lesion in AP14 cells causes abnormal regulation of MAP kinase activity and does not reside in the primary components of the RAS-RAF-MAP kinase pathway. RAF-1 is still associated with N-RAS in AP14 cells and MEK1 activity is similar in parental and mutant cells. The most obvious defect in AP14 cells is in maintaining the elevated basal phosphorylation of MAP kinase and the elevated MAP kinase activity of the parental cells. The observation that the general phosphatase inhibitor orthovanadate restored MAP kinase activity, together with corresponding increases in p53 and p21, suggests that the modulation of a phosphatase such as MKP1 may be involved in regulating MAP kinase. Although AP14 and H10 cells express comparable levels of MKP1, it is possible that the mutation of AP14 cells lies in an unknown factor that alters the activity of this phosphatase.
MAP kinase activity is regulated not only at the level of kinase and phosphatase activities but also through the association of MEK1 and ERK1 with MP1, a scaolding protein (Schaeer et al., 1998) that organizes these two proteins into an ecient signaling complex. Loss of MP1 would be expected to disorganize this connection. Although H10 and AP14 cells express comparable amounts of MP1, the defect in AP14 cells might still be due to a faulty organization of scaolding proteins in the RAS-RAF-MAP kinase cascade.
Materials and methods
Cell lines and culture conditions
All cells were grown in 10% CO 2 in Dulbecco's modi®ed Eagle's medium (DMEM), supplemented with 10% fetal bovine serum. The parental cell line for mutant AP14, HT1080, is a human ®brosarcoma containing high levels of p53. Transient transfection assays for the induction of luciferase from a p53-dependent promoter, Western analysis for induction of p53 protein and direct sequencing of the coding region of p53 (our data not shown), using the primers developed by Casey et al. (1993) , have revealed that the p53 protein in HT1080 cells is wild-type, inducible, and fully functional as a transcriptional activator. HT1080 cells do not undergo apoptosis or cell-cycle arrest when wild-type p53 is expressed at an even higher level from a constitutive promoter (our data not shown). Note that HT1080 cells have been reported by Anderson et al. (1994) to contain mutant p53. However, the cells these authors studied had been mutagenized, possibly causing the observed mutation of p53 (Eric Stanbridge, personal communication). The stable cell line H10, expressing the cell-surface marker cd2 under the control of the ConA promoter (consisting of two p53-responsive elements, a 20 bp palindromic consensus sequence (Funk et al., 1992) and a 33 bp element, fragment A (Kern et al., 1992) , was generated by co-transfecting HT1080 cells with p53conA.cd2 and pBabepuro. The expression of cd2 was induced strongly when H10 cells were treated with DNAdamaging agents or agents that arrest DNA synthesis.
Retroviral vectors
H-rasV12 (Serrano et al., 1997) , in the retroviral pBabe-puro vector (Morgenstern and Land, 1990) , was obtained from Scott Lowe, Cold Spring Harbor Laboratories. Retroviral gene transfer was performed using high titer virus, generated by transient transfection of the ecotropic packaging BOSC cells (Hua et al., 1998) . To determine the eciency of infection, a retroviral vector containing green¯uorescent protein was used (Hua et al., 1998) . NIH3T3 cells were obtained from Dennis Stacey, Cleveland Clinic Foundation. REF52 were as described by Franza et al. (1986) .
Plasmids, p53-driven reporter constructs and transfections
The plasmid pGUP.PA.8, which carries the ConA promoter, was obtained from Dr Jerry Shay (UT Southwestern Medical Center, TX, USA). The p53 consensus sequences and TATA promoter were obtained from pGUP.PA.8 by PCR. The PCR product was cloned into pDW9-27CD2 (McKendry et al., 1991) between the AccI and BamHI sites, after removing the promoter, to yield p53conA.cd2. Plasmids were stably transfected into HT1080 cells using the calcium phosphate method (Chen and Okayama, 1987) , and several puromycinresistant clones were assayed for the expression of cd2 after DNA damage. Clone H10 was used for all subsequent studies. For p53-mediated induction of luciferase, p53con-A.luc was transfected into cells transiently. After 24 h, the cells were treated to induce p53 and the activity was measured by using the luciferase assay system (Promega).
Mutagenesis and isolation of mutant cell lines
Independent pools of H10 cells were subjected to four rounds of treatment with the chemical mutagen ICR191, to approximately 70% lethality each time (McKendry et al., 1991) . The mutagenized cells (4610 7 ) from one pool were treated for 48 h with 2 mM PALA (a very high concentration, to eliminate the possibility of isolating PALA-resistant cells), stained with an antibody to cd2 and sorted by FACS. The least responsive 3 ± 5% of the cells were recovered and grown to 4610 7 cells. The entire process was carried out a total of four times, with gradual enrichment of cells that failed to induce cd2 in response to PALA. After the fourth sort, individual colonies were isolated from single cells.
Approximately 20 such clones were analysed for failure to induce functional p53 after transient transfection with p53conA.luc. Upon treatment with PALA, many of the clones were still able to induce functional p53 as judged by increased luciferase activity. These clones were probably cis mutants in which the cd2 reporter has been inactivated. Three clones expressed much lower levels of luciferase in response to PALA, compared to H10 cells, suggesting that they were trans mutants. They were analysed for induction of p53 protein after treatment with agents that either arrest DNA synthesis or damage DNA. Initial experiments suggested that the three clones were identical and therefore we characterized only AP14.
cd2 analysis and FACsorting
Analysis of cd2 induction was carried out as previously described (McKendry et al., 1991) . Cells were removed from plates with cell dissociation buer (GIBCO), washed with staining buer (1% fetal bovine serum and 0.02% sodium azide in DMEM), and treated with a phycoerythrinconjugated monoclonal antibody to cd2 (Dako Corp.) for 45 min at 48C. The cells were washed twice, resuspended in 0.5 ml of staining buer and analysed by FACscanning, using the LYSISII software (Becton-Dickinson). For FACsorting, the staining procedure was performed under sterile conditions and CELLQuest software was used (Becton-Dickinson).
Western analysis
Protein levels of p53, p21, MAP kinase and MKP1 were determined by using standard procedures. Total cellular proteins were isolated by lysing the cells in 20 mM Tris.HCl, pH 7.5, 2% (wt/vol) SDS, 2 mM benzamidine, 0.2 mM phenylmethanesulfonyl¯uoride. Protein concentrations were determined by the Bradford method (Biorad). Total proteins (25 mg) were separated by SDS ± 10% PAGE and electroblotted (Harlow and Lane, 1988) to polyvinylidene di¯uoride membranes (Stratagene). After transfer, the gels were stained with Coomassie blue to verify equal sample loading. The membranes were probed with monoclonal antibodies DO-1 (for p53), C17 (for p21), E4 (for active phosphorylated ERK1 and ERK2) and polyclonal antibody C19 (for MKP1) (Santa Cruz Biotech.). Bound antibody was detected with a secondary antibody conjugated to horseradish peroxidase by using enhanced chemiluminescence (Amersham).
Cell fusions
Cells carrying dierent drug-resistance markers were seeded together and, when 70 ± 80% con¯uent, were fused using polyethylene glycol (molecular weight, 1000) as described by Pellegrini et al. (1989) . The resulting heterokaryons were selected in both drugs for 1 week, followed by treatment with inducing agents. cd2 expression was analysed by FACscanning.
Immunoprecipitation of N-RAS/RAF-1 complexes
Cells were lysed on ice for 20 min in 500 ml of ice-cold CHAPS lysis buer (20 mM MOPS, 200 mM sucrose, pH 7.4, 1% (wt/vol) CHAPS, 10 mM MgCl 2 , 1 mM EDTA), plus protease and phosphatase inhibitors. Lysates were centrifuged at 10 000 g for 10 min at 48C to remove insoluble material. Clari®ed lysates were pre-absorbed for 10 min on ice with 200 ml of protein A sepharose and then centrifuged at 10 000 g for 5 min at 48C. The protein concentration of the lysates was determined by the Bradford method: 500 mg of cell lysates were incubated for 3 h with 50 ml of anti-N-RAS at 48C, with constant rotation. Insoluble material was pelleted by centrifugation at 10 000 g for 10 min at 48C and the lysates were transferred to Eppendorf tubes containing 400 ml protein A sepharose and rotated for an additional hour at 48C. The immunoprecipitates were collected by centrifugation and washed ®ve times with ice-cold MOPS buer (20 mM MOPS, 200 mM sucrose, pH 7.4, 10 mM MgCl 2 , 1 mM EDTA) containing 0.1% (w/v) Nonidet P40. Laemmli buer was added and the immunoprecipitates were heated for 5 min at 1008C before being separated by 8% SDS ± PAGE. The gel transfers were analysed by the Western procedure as above.
MAP kinase activity assay
Parallel cultures of H10, AP14 and AP14/ERK2 cells were grown in 10% FCS/DMEM or incubated in serum-free DMEM for 48 h. The cell monolayers were washed twice with ice-cold Tris-buered saline and lysed in CHAPS lysis buer. MAP kinase was immunoprecipitated from 250 mg of lysate for 2 h at 48C with constant rotation, using 0.5 ml of TR10 anti-MAP kinase (kindly provided by Dr MJ Weber, University of Virginia), coupled to protein A sepharose. Immunoprecipitated proteins were washed three times with MOPS buer containing 0.1% Nonidet P40 and twice with MOPS buer alone. Fifty ml of kinase buer (MOPS buer containing 10 mM ATP), 10 mCi 32 P-labeled ATP, 10 mM phosphatase inhibitors (200 mM each of phosphoserine, phosphotyrosine, phosphothreonine, b-glycerophosphate and p-nitrophenyl phosphate), with 25 mM myelin basic protein as a MAP kinase substrate, was added to each immunoprecipitate and incubated at 378C for 20 min. The kinase reaction was stopped by adding 50 ml of 26 Laemmli buer and the phosphorylated proteins were resolved by 15% SDS ± PAGE. Phosphorylated myelin basic protein was visualized and quantitated on a Molecular Dynamics PhosphoImager.
MEK1 activity assay
Lysates were prepared from serum-starved H10, AP14 and AP14/ERK2 cells as described above. MEK1 was immunoprecipitated from equal amounts of cell lysate with the speci®c monoclonal antibody anti-MEK1 (Transduction Laboratories) and incubated in 50 ml of the kinase buer described above but containing 4.0 mg of kinase-inactive GST-ERK1 (Stratagene) as a MEK1-speci®c substrate. Kinase reactions were carried out for 20 min at 378C and stopped by adding Laemmli buer. The products were analysed by 8% SDS ± PAGE and electroblotted onto a polyvinylidene di¯uoride membrane. Phosphorylated GST-ERK1 was visualized using a Molecular Dynamics StormImager.
RNA analyses
Northerns were performed as described by Sambrook et al. (1989) . Total RNA was extracted with the Trizol reagent (BIBCO ± BRL) as speci®ed by the manufacturer. For RNase protection analyses, an EcoRI/ApaI fragment containing 320 base pairs from the 5' region of p21 cDNA was removed from pZL-waf1 (a gift of Wa®k El-Deiry, University of Pennsylvania, PA, USA) and cloned into the multicloning site of Bluescript KS, digested with EcoRI/ApaI, to produce pBLWAF. pBLWAF was digested with PvuII, which cleaves at a site within the original 320 base pair p21/Waf1 fragment. In vitro transcription with T3 polymerase produced an antisense RNA terminating at the PvuII site and containing 155 nucleotides complimentary to the p21 sequence. This RNA was used for RNase protection as described below. Gadd45 cDNA (a gift from Albert Fornace, National Cancer Institute, MD, USA) was digested with BamHI/EcoRI to release a 395 base pair fragment from the 5' region. This fragment was cloned into Bluescript KS, digested with BamHI/EcoRI, to produce pBLGAD, which was digested with PstI (at a site present in the original gadd45 BamHI/ EcoRI fragment). The ends were made blunt with T4 DNA polymerase. Transcription using T7 polymerase generated an antisense RNA terminating at the PstI end, which was used for RNase protection. The probe contains a 196 nucleotide region complementary to gadd45. The g-actin probe (which protects 130 nucleotides) and the RNase protection assay were described by Leung et al. (1995) . Brie¯y, in vitro transcription in the presence of 32 P-labeled UTP generated labeled RNA probes for waf1, gadd45 and g-actin which were incubated all together with total cellular RNA at 508C for 16 h to allow hybridization. Unhybridized single-stranded RNA was digested with RNase T2 and the protected fragments collected by ethanol precipitation were separated in polyacrylamide gels in 7M urea.
